Radiotherapy + Sintilimab + Bevacizumab Biosimilar for uHCC With PVTT

NCT05530785 | Unknown

• 1 other identifier: uHCC with PVTT
• Study Type: interventional
• Target: 35
• Locations: 1 country
• Sites: 1

Brief Summary

This study was a prospective, single-arm, single-center, phase II exploratory clinical study. To investigate the efficacy and safety of radiotherapy combined with sintilimab and bevacizumab biosimilar in the treatment of unresectable hepatocellular carcinoma with portal vein tumor thrombus.

Conditions

Hepatocellular Carcinoma Non-resectable

Outcome Measures

Primary Outcomes (1)

• Objective Response rate

  assessed according to the Response Evaluation Criteria in Solid Tumors RECIST Version 1.1, undergoing enhanced CT/MRI

  up to 2 years from enrollment

Secondary Outcomes (3)

• Objective Response rate, assessed according to the modified Response Evaluation Criteria

  up to 2 years from enrollment

• overall survival

  up to 2 years from enrollment

• number of participants with treatment-related adverse events

  up to 2 years from enrollment

Study Arms (1)

treatment group

EXPERIMENTAL

radiotherapy combined with sintilimab and bevacizumab biosimilar

Combination Product: radiotherapy combined with sintilimab and bevacizumab biosimilar

Interventions

radiotherapy combined with sintilimab and bevacizumab biosimilar COMBINATION_PRODUCT

After signing informed consent, patients received sintilimab 200 mg intravenously on the first day of each cycle, Q3W; Bevacizumab biosimilar 7.5mg/kg was administered intravenously on the first day of each cycle, Q3W; Concurrent radiotherapy (single dose 3-8Gy, times 3-10, total dose 20-50Gy; The duration of radiotherapy was completed between the first administration of sintilimab and the second administration of bevacizumab, but it should be noted that the interval between before and after the administration of sintilimab and bevacizumab was at least 3 days.

treatment group

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Hepatocellular carcinoma confirmed by histology/cytology, or patients with cirrhosis and meet the American Association for the Study of Liver Diseases (AASLD) clinical diagnostic criteria for HCC
• Child-pugh grade A or B (≤7 points)
• A score of 0-1 according to the Eastern Cooperative Oncology Group Physical Status Score (ECOG PS score);
• Barcelona stage C; Inamicable for radical surgical resection or refusal of surgery without extra-hepatic metastases; Portal vein tumor thrombus (PVTT) was diagnosed by enhanced CT or enhanced MRI (type VP1 to VP3).
• Had not received systemic therapy or radiotherapy before; Or disease progression after surgical resection or local treatment (without radiotherapy);
• At least one measurable or evaluable lesion according to the response evaluation criteria for solid tumors, version 1.1 (RECIST V1.1); Or measurable lesions that had clearly progressed after local treatment (based on RECIST V1.1 criteria).
• Patients with liver lesions and/or portal vein tumor thrombus lesions were treated with radiotherapy

You may not qualify if:

• Previous histological/cytological diagnosis included fibrolamellar hepatocellular carcinoma, sarcomatoid hepatocellular carcinoma, cholangiocarcinoma, and other components.
• The area to be treated had been previously treated with radiotherapy
• Patients with extrahepatic metastases
• Patients with tumor thrombus invasion into the superior mesenteric vein
• Patients with inferior vena cava tumor thrombus.
• Central nervous system metastases were present.
• A history of hepatic encephalopathy, or a history of liver transplantation.
• There are clinical symptoms of pleural effusion, ascites, or pericardial effusion that require drainage.
• Patients with acute or chronic active hepatitis B or C with hepatitis B virus (HBV) DNA\>2000IU/ml or 10\^4 Copies/ml; Hepatitis C virus (HCV)RNA\> 10\^3 Copies/ml; Hepatitis B surface antigen (HbsAg) and anti-HCV antibody were both positive.
• History of allergy to active ingredients and/or excipients of anti-PD-1 mab and anti-VEFG mab.
• Other malignancies, except cured basal cell carcinoma of the skin and carcinoma in situ of the cervix, were present within 5 years.
• Bleeding events from esophageal or gastric fundus varices due to portal hypertension had occurred within the previous 6 months. Severe (G3) varicose veins were known to have been present on endoscopy within 3 months before the first dose. There was evidence of portal hypertension (including splenomegaly on imaging) and a high risk of bleeding as assessed by the investigator.

Sponsors & Collaborators

• Yongchang Zhang: lead

Study Sites (1)

Hunan Cancer Hospital

Changsha, Hunan, 410013, China

RECRUITING

MeSH Terms

Interventions

sintilimab

Study Officials

• Jia Luo, Professor

  Hunan Cancer Hospital

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Jia Luo, Professor

CONTACT

86-0731-89762031; luojia@hnca.org.cn

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Professor

Study Record Dates

• First Submitted: August 27, 2022
• First Posted: September 7, 2022
• Study Start: August 1, 2022
• Primary Completion: October 1, 2024
• Study Completion: October 1, 2024
• Last Updated: September 7, 2022

Record last verified: 2022-09

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)